Fig. 4.

ROS formation occurs through ligation and activation of GPIbα. (A) H₂DCFDA labelled human platelets were stimulated with WT or R543W COS-7 cells (1:50; cell:platelet ratio) and monitored for ROS production by flow cytometry. Data are mean±SEM (n=3). (B) H₂DCFDA labelled human platelets pre-treated with either the GPIbα-function blocking antibody, AK2 (20 µg/mL) or the VWF-function blocking antibody 5D2 (10 µg/mL) were stimulated with R543W cells (1:50; cell:platelet ratio) and monitored for ROS production. Data are mean±SEM (n=3). *P≤0.05, **P≤0.01, ***P≤0.001.